KalVista Pharmaceuticals, Inc. SEC Filings

Point72 Asset Management, Point72 Capital Advisors Inc. and Steven A. Cohen report beneficial ownership of 2,136,940 shares of KalVista Pharmaceuticals common stock, representing 4.2% of the class as of the close of business on March 31, 2026, pursuant to Amendment No. 2 to a Schedule 13G/A.

The filing states the shares are held by an investment fund managed by Point72 Asset Management, with shared voting and dispositive power reported. The reporting persons state they directly own no shares and that Point72 Asset Management maintains investment and voting power for the fund.

KalVista Pharmaceuticals reported its first meaningful commercial quarter as EKTERLY sales drove total revenue of $40.9M for the three months ended March 31, 2026, up from zero a year earlier. Product revenue reached $39.2M, largely from U.S., Germany and Japan launches, while partnership revenue contributed $1.7M.

Operating expenses rose to $64.3M, mainly from higher commercial and administrative spending, but the net loss narrowed to $23.5M (basic and diluted loss per share $0.43) from $51.8M in the prior-year quarter. KalVista ended the period with cash, cash equivalents and marketable securities totaling $285.0M, which management believes is sufficient to fund operations for at least twelve months.

Separately, KalVista agreed to be acquired by Chiesi through a tender offer at $27.00 per share in cash, followed by a merger that would take the company private, subject to a majority tender, regulatory clearances and other customary conditions. If the merger is not completed under certain circumstances, KalVista could owe Chiesi a $66.4M termination fee.

KalVista Pharmaceuticals, Inc. recommends that stockholders tender their shares to Purchaser in a cash tender offer of $27.00 per share. If the Offer is consummated and accepted, Purchaser will merge into the company and KalVista will become a wholly owned subsidiary of Parent.

As of May 6, 2026, there were 53,240,888 Shares outstanding. The Offer’s initial expiration is one minute after 11:59 p.m. Eastern Time on June 10, 2026. The Merger Agreement includes a $66.4 million termination fee and details treatment of outstanding options, RSUs, warrants, ESPP rights, executive transaction bonuses, and estimated golden‑parachute payments.

KalVista Pharmaceuticals Inc is reported as having 2,876,407 shares of Class A Common Stock beneficially owned by SilverArc Capital Management, LLC and Devesh Gandhi, representing 5.6% of the class as of 03/31/2026.

The filing states SilverArc acts as investment adviser to multiple funds that together account for the disclosed position, with specific allocations to named funds listed in the report.

KalVista Pharmaceuticals, Inc. chief executive Benjamin L. Palleiko reported routine equity compensation activity and related tax sales. On May 11, 2026, he exercised 7,120 restricted stock units, receiving an equal number of common shares for no cash cost as the units vested.

On May 12, 2026, he sold 3,322 common shares at $26.71 per share to cover tax withholding obligations from this vesting. A footnote explains this “sell to cover” transaction did not represent a discretionary sale decision. After these transactions, he directly owned 466,375 common shares, with additional RSUs remaining outstanding.

Skyline Merger Sub, Inc., a wholly owned subsidiary of Chiesi Farmaceutici S.p.A., is offering to acquire all outstanding shares of KalVista Pharmaceuticals, Inc. for $27.00 per share in cash pursuant to the Offer to Purchase dated May 13, 2026.

The Company reported 53,240,888 Shares outstanding as of May 6, 2026. The Schedule TO also lists 4,789,390 options, 3,686,552 restricted stock units, 46,104 ESPP purchase rights, 1,630,000 warrants, and 8,551,960 Shares reserved for conversion of the convertible senior notes. The Merger Agreement dated April 29, 2026 among Parent, Purchaser, the Company and KalVista UK is incorporated by reference.

Chiesi Farmaceutici and its subsidiary Skyline Merger Sub have outlined a proposed cash tender offer to acquire KalVista Pharmaceuticals for $27.00 per share under an Agreement and Plan of Merger dated April 28, 2026. The communication is a preliminary solicitation and states the Offer has not yet commenced.

The filing says Offer materials (a Schedule TO by Parent and Purchaser and a Schedule 14D-9 by KalVista) will be filed with the SEC when the Offer is launched; investors are directed to review those materials and the companies' SEC filings for details.

KalVista Pharmaceuticals, Inc. Schedule 13G/A amendment discloses passive, shared voting and dispositive power over 1,546,105 shares (3.0%) by Integrated Core Strategies (US) LLC and 1,912,146 shares (3.7%) by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filing is a joint filing under a Joint Filing Agreement dated April 30, 2026.

The filing lists shared voting and disposition powers and clarifies the securities are held by entities subject to Millennium-related voting or investment discretion; signatures are provided by Gil Raviv and Israel A. Englander.

KalVista Pharmaceuticals, Inc. filed Amendment No. 1 to its transition Form 10-KT to add the disclosures required by Part II and Part III and to furnish new Section 302 certifications. The Amendment also discloses that on April 29, 2026 the company and certain subsidiaries entered into an Agreement and Plan of Merger providing for the acquisition of KalVista by Chiesi Farmaceutici S.p.A. through a merger in which KalVista will become a wholly owned subsidiary of Chiesi.

The Amendment restates that its Original Filing continues to speak as of the Original Filing date and that no other updates were made. It includes board and executive officer biographies, executive compensation disclosures for the 2025 transition period, equity plan and outstanding award tables, related-party transactions (including participation by certain holders in the November 2024 offering), and auditor fee disclosures.